Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Operating expenses: | ||
| General and administrative expenses | $4,823,378 | $2,707,851 |
| Research and development | 5,980,477 | 1,975,074 |
| Total operating expenses | 10,803,855 | 4,682,925 |
| Loss from operations | (10,803,855) | (4,682,925) |
| Other income (expense): | ||
| Interest income | 717,168 | 150,219 |
| Total other income (expense), net | 717,168 | 150,219 |
Document
FAQ
- What is Immix Biopharma, Inc.'s R&D?
- Immix Biopharma, Inc. (IMMX) reported R&D of $5.98M in Q1 2026.
- How has Immix Biopharma, Inc.'s R&D changed year-over-year?
- Immix Biopharma, Inc.'s R&D increased by 202.8% year-over-year, from $1.98M to $5.98M.
- What is the long-term trend for Immix Biopharma, Inc.'s R&D?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s R&D has grown at a 236.7% compound annual growth rate (CAGR), from $126.53K to $16.26M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Immix Biopharma, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude